Recommendation of the President – Amvuttra (vutrisiran)
On 12 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 123/2024 on the appraisal of the drug Amvuttra (vutrisyrate) under the drug program “Treatment of adult patients with stage I or II polyneuropathy in the course of hereditary transthyretin amyloidosis (ICD-10: E85.1)”